Outcome of early switching of Tenofovir Disoproxil Fumarate (TDF) in HIV-infected patients with TDF-induced nephrotoxicity: a prospective study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20190307003

Enrollment

Registered

2019-03-07

Start date

2017-09-30

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TDF&#45

Interventions

Early&#45

switching of TDF to alternative ART,Late&#45

switching of TDF to alternative ART

Experimental Other,Experimental Other

switching of TDF,Late&#45

switching of TDF

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: HIV-infected adult age of 18 years old or more plus the followings: 1) on TDF-containing regimen 2) no documented HIV drug resistance 3) evidence of proximal renal tubulopathy (PRT) 4) protease inhibitor-naÃ¯ve patients

Exclusion criteria

Exclusion criteria: 1) any concomitant kidney disease or abnormal urinary sediments before TDF initiation 2) nephrotoxic agents or MRP-4 inhibitors use in the previous 28 days prior to recruitment 3) pregnant patients 4) documented obstructive uropathy including BPH and stones 5) SGLT-2 inhibitors use.

Design outcomes

Primary

Measure	Time frame
Complete recovery of proximal tubular markers 1 year Tubular markers	—

Secondary

Measure	Time frame
Virological outcome 1 year HIV viral load	—

Contacts

Public ContactSamadhi Patamatamkul

Chulalongkorn University

samadhi.p@msu.ac.th66815441374

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Outcome of early switching of Tenofovir Disoproxil Fumarate (TDF) in HIV&#45;infected patients with TDF&#45;induced nephrotoxicity: a prospective study